Pages

Monday, 21 July 2014

Johnson & Johnson: sentiment high, price struggling to move on...take a few profits

Back in April I talked about selling a few Johnson & Johnson shares (short) above US$100.  Since then the shares are up a touch but effectively have not broken out:



Last week's numbers were headline strong with either side of double digit gains in sales and various earnings indicators for the Q2 period year-on-year (helped slightly be easy comparisons, for reference purposes the Q1 year-on-year growth statistics were in the 5%s making the sequential H1 numbers consistent with a 7-8% earnings growth profile):

As I noted in the above April link, the real driver in the company nowadays is not the high profile consumer business but the pharmaceutical division which is over double the size and far more profitable.  Progress here was good driven by new products and enhanced market shares:

The pharmaceutical business has performed very well...

...driven by new products:

So how much more of this to go?  The company talked about '25 line extensions' in their Q2 press release  and this is all-critical given the other divisions (consumer and medical devices) only grew a couple of percent collectively over the last year.  My observation from the above is that sentiment towards the division must be very high.

Johnson & Johnson is not a dangerous share (US$10bn of net cash, getting on for 5% free cash flow yield, just over half of this paid out as a dividend) but even an optimistic view of earnings next year places it in the x12s EV/ebit.  I still prefer to see a price below US$90 to consider putting capital at the margin to work in the company and - ahead of the deep summer - I still think current investors in the stock should take a few profits.

No comments:

Post a Comment